[HTML][HTML] Impact of the coronavirus disease 2019 pandemic on cancer treatment: the patients' perspective

…, IH Dingemans, AC Dingemans… - European journal of …, 2020 - Elsevier
Background The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute
respiratory syndrome coronavirus 2, has inevitable consequences for medical care of …

[HTML][HTML] Pre-cachexia in patients with stages I–III non-small cell lung cancer: systemic inflammation and functional impairment without activation of skeletal muscle …

…, FJ Snepvangers, MK Hesselink, AC Dingemans… - Lung cancer, 2012 - Elsevier
Cachexia is a prevalent phenomenon of non-small cell lung cancer (NSCLC) which is responsible
for increased mortality and deterioration of physical performance. Preclinical research …

[HTML][HTML] Trastuzumab-emtansine and osimertinib combination therapy to target HER2 bypass track resistance in EGFR mutation-positive NSCLC

…, SMS Hashemi, MS Paats, AC Dingemans… - JTO clinical and …, 2023 - Elsevier
Introduction EGFR tyrosine kinase inhibitor improved the survival of patients with metastatic
EGFR mutation-positive (EGFRm+) NSCLC. Despite high response rates, resistance …

[HTML][HTML] The value of prognostic and predictive parameters in early-stage lung adenocarcinomas: A comparison between biopsies and resections

…, DAM Mustafa, JM Kros, AP Stubbs, AC Dingemans… - Lung Cancer, 2023 - Elsevier
Introduction Since lung adenocarcinoma (LUAD) biopsies are usually small, it is questionable
if their prognostic and predictive information is comparable to what is offered by large …

[HTML][HTML] Cost-effectiveness of proton radiotherapy versus photon radiotherapy for non-small cell lung cancer patients: Exploring the model-based approach

…, C Oberije, J van Loon, AC Dingemans… - Radiotherapy and …, 2023 - Elsevier
Introduction Proton radiotherapy (PT) is a promising but more expensive strategy than
photon radiotherapy (XRT) for the treatment of non-small cell lung cancer (NSCLC). PT is …

[BOOK][B] Water wave propagation over uneven bottoms: Linear wave propagation

MW Dingemans - 2000 - books.google.com
This book is concerned with wave-propagation problems in coastal areas. Not the specific
application to engineering problems in these areas is subject of this book, but attention is …

[HTML][HTML] Osimertinib Plasma Trough Concentration in Relation to Brain Metastases Development in Patients With Advanced EGFR-Mutated NSCLC

…, S Dursun, EF Smit, AMC Dingemans… - JTO Clinical and …, 2024 - Elsevier
… /mL, because we found that a large proportion of our patients had a C min above this value.
Dingemans reports receiving grants or contracts from Amgen, Dutch Cancer Society and …

A phase II study of erlotinib and sorafenib in chemotherapy-naive patients with locally advanced/metastatic non-small cell lung cancer (NSCLC)

JS Lind, AC Dingemans, HJ Groen… - Journal of Clinical …, 2009 - ascopubs.org
8018 Background: This multicentre, phase II study evaluates efficacy and safety of erlotinib,
an EGFR inhibitor, and sorafenib, a multi-kinase inhibitor, in advanced NSCLC. In addition …

[HTML][HTML] Results of screening in early and advanced thoracic malignancies in the EORTC pan-European SPECTAlung platform

…, J Vansteenkiste, L Lacroix, AC Dingemans… - Scientific reports, 2022 - nature.com
Access to a comprehensive molecular alteration screening is patchy in Europe and quality
of the molecular analysis varies. SPECTAlung was created in 2015 as a pan-European …

A randomized phase II study of pemetrexed (P) versus pemetrexed-carboplatin (PC) as second line treatment for patients (pts) with advanced non-small-cell lung …

…, B Biesma, P Eppinga, AC Dingemans… - Journal of Clinical …, 2008 - ascopubs.org
8050 Background: The role of platinum compounds as part of second line therapies in advanced
NSCLC is ill defined. We performed a randomized phase II trial comparing P and PC in …